V4b Toric implantable collamer lens for myopic astigmatism: one year follow-up

Session Details

Session Title: Presented Poster Session 19: Phakic IOLs 2

Session Date/Time: Tuesday 16/09/2014 | 09:30-11:00

Paper Time: 10:00

Venue: Pod 1 (Poster Village)

First Author: : T.Ferrer-Blasco SPAIN

Co Author(s): :    J. Alfonso   L. Fernández-Vega   C. Lisa   R. Montes-Mico     

Abstract Details

Purpose:

To assess the predictability, stability, safety and efficacy of the V4b toric Implantable Collamer lens (TICL) model to correct moderate and high astigmatism

Setting:

Instituto Oftalmológico Fernández-Vega, Oviedo, Spain

Methods:

This study evaluated eyes that had implanted of a TICL V4b model. Uncorrected (UDVA) and corrected distance visual acuity (CDVA), refraction, TICL vault and adverse effects were evaluated over 12 months

Results:

The study included 35 eyes of 20 patients, the mean sphere was -5.46 diopters (D) ± 4.17 (SD) (range +3 to -12 D) and the mean cylinder, -3.14 ± 1.19 D (range -1.50 to -6). At 12 months, the mean sphere was -0.04 ± 0.16 D (range 0 to -0.75) with 97% of the eyes within ± 0.50 D of the target (r2=0.99). The mean cylinder was -0.29 ± 0.42 D (range 0 to -1) with 65% of the eyes having less than 0.25 D of refractive cylinder. For both astigmatism components 80% of eyes were within ±0.25 D of J0 (r2=0.99) and J45 (r2=0.99), respectively. All eyes were within ±0.50 D of the desired refraction. The mean Snellen decimal UDVA was 0.89 ± 0.16 and mean CDVA, 0.95 ± 0.12; 77% had CDVA of 20/20. No eyes lost any line of CDVA and 43% of eyes gained 1 line or more. The safety index was 1.08 at 12 months. More than 50% of eyes had UDVA of 20/20; the efficacy index was 0.97 at 3 months and 1.01 at one year.

Conclusions:

The visual and refractive outcomes were good and highly stable throughout the follow-up period; showing that this TICL model is predictable, stable, safe and effective to correct low and high levels of astigmatism.

Financial Interest:

NONE